2026-10-25
AgomAb Therapeutics clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,990 +1.35%
S&P 7,377 +0.31%
GOLD $4,075 −0.94%
BTC $75,677 −0.09%
VIX 25.64 −9.01%
latest tape · as of 20:08 UTC
The Screen · Healthcare · Biotechnology
AgomAb Therapeutics NV
AGMB · Nasdaq · USD · Market cap $428M · 62 employees
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States.
Not yet scored7.64 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price7.64 USD at the 6 Nov 2026 close
- Fair valueUnder review: its inputs are 11 days old; the analyst targets sit too far from the price to cross-check it.
- Our regime readMarkdown, as of 7 Nov 2026
- Ethical screenNot yet scored
- Last reviewed6 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: range not available (screen dated 2026-11-06).
- Trend Markdown
- Insiders insiders bought, latest filing 2026-10-21
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price7.64 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-03Read Markdown7.49+1.9% to today Distribution gives way to Markdown after a 53% slide in 6 weeks
2026-09-21Read Distribution15.78-51.6% to today ✓Markup gives way to Distribution after a 15% rise in 4 weeks
2026-08-21Read Markup13.75-44.5% to today Markdown gives way to Markup after a 43% rise in 7 weeks
2026-07-02Read Markdown9.61-20.6% to today ✓First review on file: Markdown
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markdown label.
AgomAb Therapeutics NV holds its Markdown at $7.64. The statistical read favours the sellers, held for 21 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the sellers, held for 21 days |
| Price at the screen | $7.64 |
| Valuation | N/A trailing · -4.24 forward price to earnings |
| Values screen | Not scored · score 70.0 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 0.22% | Below 33% | Interest-bearing debt is just 0.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 20.05% | Below 33% | Cash held in interest-bearing accounts and securities is 20.0% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
AgomAb Therapeutics clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
AgomAb Therapeutics clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value under review. Its inputs are 11 days old; the analyst targets sit too far from the price to cross-check it. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets: 6 covering, consensus Strong Buy. The average target sits +352% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -4.2x |
| EPS, trailing | -2.08 |
| EPS, forward | -2.05 |
| Profit margin | 0.0%currently unprofitable |
| Debt to equity | 0.43minimal debt: a conservative balance sheet |
| Current ratio | 12.88comfortably covers its short-term bills |
| Short interest, float | 0.02% |
| 52-week range | 7.97 - 17.82 |
| Market cap | $428M |
| Employees | 62 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Belgium and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeAGMB trades on Nasdaq (the company is based in Belgium). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-03
Markdown · changed $7.49
-10.1% Entry 11
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (3 analysts) rates it none, with a mean price target of $32. Insiders have been net buyers over the past quarter.
2026-10-27
Distribution $8.33
-8.3% Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.3% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (3 analysts) rates it none, with a mean price target of $32. Insiders have been net buyers over the past quarter.
2026-10-12
Distribution $9.08
-14.2% Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 14.2% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (3 analysts) rates it none, with a mean price target of $32.
2026-10-02
Distribution $10.58
-33.0% Entry 8
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 33.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (3 analysts) rates it none, with a mean price target of $32.
2026-09-21
Distribution · changed $15.78
+14.8% Entry 7
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 14.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (3 analysts) rates it none, with a mean price target of $32.
2026-08-21
Markup · changed $13.75
+14.2% Entry 6
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (3 analysts) rates it none, with a mean price target of $32.
2026-07-20
Markdown $12.04
+25.3% Entry 5
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 25.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (3 analysts) rates it none, with a mean price target of $32.
2026-07-18
Markdown $9.61
+0.0% Entry 4
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (3 analysts) rates it none, with a mean price target of $32.
2026-07-16
Markdown $9.61
+0.0% Entry 3
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bullish. Our forward projection puts the odds of a 10% gain over the next month near 21%. The street (3 analysts) rates it none, with a mean price target of $32.
2026-07-03
Markdown $9.61
+0.0% Entry 2
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation Yahoo Finance · 8 Oct 2026
- Agomab stock jumps on positive trial data Yahoo Finance · 1 Oct 2026
- Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease Yahoo Finance · 1 Oct 2026
- Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study Yahoo Finance · 14 Sep 2026
- Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Yahoo Finance · 11 Sep 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
PRTCYPureTech Health plc
EPRXEupraxia Pharmaceuticals Inc
PRTCProtech Inc
RLMDRelmada Therapeutics, Inc.
TENXTenax Therapeutics Inc
BNTCBenitec Biopharma Inc
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | Epstein David R | Dir | P - Purchase | 10,000 | $88,800 |
| 2026-10-08 | Epstein David R | Dir | P - Purchase | 5,000 | $44,500 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $12.18 | -13.7% | · | $863 | -13.7% |
| 2 months | $10.54 | -0.2% | · | $998 | -0.2% |
| 3 months | $13.91 | -24.4% | · | $756 | -24.4% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AGMB does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.